T-Cell Immunotherapy Market, 2018-2030 - ResearchAndMarkets.com

June 8, 2018

DUBLIN--(BUSINESS WIRE)--Jun 8, 2018--The “T-Cell Immunotherapy Market (3rd Edition), 2018-2030” report has been added to ResearchAndMarkets.com’s offering.

The “T-Cell Immunotherapy Market, 2018-2030 (3rd edition)” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies (focusing particularly on CAR-T therapies, TCR therapies and TIL therapies). One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing development programs of both small and big pharmaceutical firms.

Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2017 in the US alone. The World Health Organization states that the number of new cancer cases globally is expected to rise by 70% in the coming 20 years. Although cancer therapeutics continue to be one of the most active areas in terms of drug development, there is still a significant unmet need in this domain. Conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Specifically, chemotherapy and radiation therapy are also associated with several side effects. Their non-specific nature has severe detrimental effects on the patients’ quality of life.

Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to eradicate tumor cells with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. It encompasses several treatment approaches, such as monoclonal antibodies, immune checkpoint inhibitors, therapeutic vaccines, cytokine therapies and cell-based therapies. In recent years, adoptive T-cell therapy (ACT) has emerged as a potent and viable therapeutic intervention. There are certain key characteristics that render T-cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory.

Close to 120 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential product candidates. These efforts have built the intellectual framework for the establishment of several start-ups; in fact, during the last five years, over USD 8 billion has been invested by VC firms/other strategic investors. It is also worth highlighting that there have been more than 200 instances of collaborations between industry/academic stakeholders.

The ongoing innovation has also led to the discovery of several novel molecular targets, strengthening the research pipelines of various companies engaged in this domain. Encouraged by the recent approval of two CAR-T therapies, namely Kymriah (Novartis) and Yescarta (Gilead Sciences), and a robust development pipeline, the T-cell immunotherapy market offers considerable promise to a number of industry stakeholders.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Emerging Trends On Social Media

5. Market Landscape

6. Key Insights

7. Chimeric Antigen Receptor-T Cell Therapy

8. T-Cell Receptor (Tcr) Based Therapies

9. Tumor Infiltrating Lymphocytes (Til) Based Therapies

10. Key Therapeutic Areas For T-Cell Therapies

11. Emerging Technologies

12. Partnerships And Collaborations

13. Funding And Investment Analysis

14. Other T-Cell Immunotherapies

15. Case Study: Cell Therapy Manufacturing

16. T-Cell Immunotherapy: Cost Price Analysis

17. Market Sizing And Opportunity Analysis

18. Promotional Analysis

19. Company Profiles

20. Conclusion

21. Executive Insights

22. Appendix 1: Tabulated Data

23. Appendix 2: List Of Companies

For more information about this report visit https://www.researchandmarkets.com/research/k3zqsx/tcell?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180608005684/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/08/2018 02:44 PM/DISC: 06/08/2018 02:44 PM


Update hourly